81764
document
Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients : a double-blind placebo-controlled study . A 6 week double-blind placebo-controlled trial of cyproheptadine augmentation of ongoing haloperidol treatment was conducted in 40 chronic schizophrenic in-patients . Cyproheptadine augmentation , compared to administration of haloperidol with placebo , did not produce a statistically significant improvement in psychotic symptoms . Cyproheptadine augmentation caused significant reduction in the extrapyramidal symptoms , which supports the atypical profile of antipsychotics . As to the neuroendocrinological effect , cyproheptadine augmentation did not reduce the plasma prolactin level but did induce a decrease in the plasma cortisol level . Although long-term follow-up studies are needed to confirm the results , this study suggests that cyproheptadine augmentation may be effective in treating chronic schizophrenic patients who are intolerant of extrapyramidal side effects of conventional antipsychotics .
81765
Intervention_Pharmacological
haloperidol
81766
Intervention_Control
placebo-controlled
81767
Intervention_Pharmacological
cyproheptadine augmentation
81768
Intervention_Pharmacological
haloperidol
81769
Intervention_Pharmacological
haloperidol
81770
Intervention_Control
placebo
81771
Outcome_Mental
psychotic symptoms
81772
Outcome_Physical
extrapyramidal symptoms
81773
Outcome_Physical
neuroendocrinological effect
81774
Outcome_Physical
plasma prolactin level
81775
Outcome_Physical
plasma cortisol level
81776
Outcome_Mental
chronic schizophrenic patients
81777
Outcome_Adverse-effects
extrapyramidal side effects
81778
Participant_Condition
chronic schizophrenic
81779
Participant_Sample-size
40